Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial

•There is a rationale to support the use of hypofractionation and dose escalation in localized prostate cancer.•The toxicity profile and local control with ultra-hypofractionated radiation therapy (UHF) and a brachytherapy boost (BB) compares favorably with the other standard moderate hypofractionated regimens.•UHF significantly reduces treatment time and is more convenient for patients.